Form 8-K - Current report:
SEC Accession No. 0001731122-21-000974
Filing Date
2021-05-28
Accepted
2021-05-28 16:00:49
Documents
16
Period of Report
2021-05-25
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K e2796_8-k.htm   iXBRL 8-K 41768
2 EX-3.1 e2796_ex3-1.htm EX-3.1 2624
3 GRAPHIC img_001.jpg GRAPHIC 408990
4 GRAPHIC img_002.jpg GRAPHIC 314572
5 GRAPHIC img_003.jpg GRAPHIC 96007
  Complete submission text file 0001731122-21-000974.txt   1351623

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE avxl-20210525.xsd EX-101.SCH 3017
7 XBRL LABEL FILE avxl-20210525_lab.xml EX-101.LAB 34238
8 XBRL PRESENTATION FILE avxl-20210525_pre.xml EX-101.PRE 22353
9 EXTRACTED XBRL INSTANCE DOCUMENT e2796_8-k_htm.xml XML 3814
Mailing Address 51 W 52ND STREET, 7TH FLOOR NEW YORK NY 10019-6163
Business Address 51 W 52ND STREET, 7TH FLOOR NEW YORK NY 10019-6163 800-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 208365999 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37606 | Film No.: 21979983
SIC: 8731 Services-Commercial Physical & Biological Research